Methods and Compositions for Inducing an Immune Response Against Multiple Antigens
Methods and compositions for inducing an immune response against multiple antigens are provided herein. In one aspect, the invention provides a chimeric immunogen, comprising a receptor binding domain, a translocation domain, and more than one non-contiguous heterologous antigen. In other aspects, the invention provides nucleic acids encoding chimeric immunogens of the invention, kits comprising chimeric immunogens of the invention, cells expressing chimeric immunogens of the invention, and methods or using chimeric immunogens of the invention. 1 mggkwskssv igwptvrerm rraepaadrv gaasrdlekh gaitssntaa tnaacawlea 61 qeeeevgfpv tpqvplrpmt ykaavdlshf lkekgglegl ihsqrrqdil dlwiyhtqgy 121 fpdwqnytpg pgvrypltfg wcyklvpvep dkieeankge ntsllhpvsl hgmddperev 181 lewrfdsrla fhhvarelhp eyfknc
1 . A chimeric immunogen, comprising:
a)—a cell surface receptor binding domain,
b)—an exotoxin translocation domain, and
c)—more than one non-contiguous heterologous antigen.
2 . The chimeric immunogen of claim 1 , wherein said cell surface receptor binding domain is selected from the group consisting of domain Ia of Pseudomonas exotoxin A; a receptor binding domains from cholera toxin, diptheria toxin, shiga toxin, or shiga-like toxin; a monoclonal antibody, a polyclonal antibody, or a single-chain antibody; TGFα, TGFβ, EGF, PDGF, IGF, or FGF; IL-1, IL-2, IL-3, or IL-6; and MIP-1α, MIP-1b, MCAF, or IL-8.
3 . The chimeric immunogen of claim 2 , wherein said cell surface receptor binding domain is domain Ia of Pseudomonas aeruginosa exotoxin A.
4 . The chimeric immunogen of claim 3 , wherein said domain Ia of Pseudomonas aeruginosa exotoxin A has an amino acid sequence that is SEQ ID NO.: 1.
5 . The chimeric immunogen of claim 1 , wherein said exotoxin translocation domain is selected from the group consisting of domain II of Pseudomonas aeruginosa exotoxin A, diptheria toxin, pertussis toxin, cholera toxin, heat-labile E. coli enterotoxin, shiga toxin, and shiga-like toxin.
6 . The chimeric immunogen of claim 5 , wherein said exotoxin translocation domain is domain II of Pseudomonas aeruginosa exotoxin A.
7 . The chimeric immunogen of claim 6 , wherein said domain II of Pseudomonas aeruginosa exotoxin A has an amino acid sequence that is SEQ ID NO.: 2.
8 . The chimeric immunogen of claim 1 , wherein at least one of said antigens is connected with said exotoxin translocation domain or said cell surface receptor binding domain with a covalent bond.
9 . The chimeric immunogen of claim 8 , wherein said covalent bond is a peptide bond.
10 . The chimeric immunogen of claim 1 , wherein at least one of said antigens is from a pathogen.
11 . The chimeric immunogen of claim 1 , wherein at least one of said antigens is from a cancer cell.
12 . The chimeric immunogen of claim 1 , wherein at least two of said antigens are from the same antigenic molecule.
13 . The chimeric immunogen of claim 1 , wherein none of said antigens is from the same antigenic molecule.
14 . The chimeric immunogen of claim 1 , wherein at least one of said antigens is a B cell antigen.
15 . The chimeric immunogen of claim 1 , wherein at least one of said antigens is a T cell antigen.
16 . The chimeric immunogen of claim 1 , wherein at least one of said antigens is a B cell antigen and at least one of said antigens is a T cell antigen.
17 . The chimeric immunogen of claim 1 , wherein at least one of said antigens is a peptide or polypeptide antigen.
18 . The chimeric immunogen of claim 14 , wherein at least two of said antigens are from the same peptide or polypeptide.
19 . The chimeric immunogen of claim 14 , wherein none of said antigens is from the same peptide or polypeptide.
20 . The chimeric immunogen of claim 14 , wherein all of said antigens are peptide or polypeptide antigens.
21 . The chimeric immunogen of claim 20 , wherein at least two of said antigens are from the same peptide or polypeptide.
22 . The chimeric immunogen of claim 20 , wherein none of said antigens is from the same peptide or polypeptide.
23 . The chimeric immunogen of claim 1 , wherein said chimeric immunogen further comprises at least a portion of domain Ib of Pseudomonas aeruginosa exotoxin A and at least one of said antigens is inserted into said domain Ib.
24 . The chimeric immunogen of claim 23 , wherein said antigen that is inserted into domain Ib of Pseudomonas aeruginosa exotoxin A is the V3 loop of HIV gp120 protein.
25 . The chimeric immunogen of claim 24 , wherein said V3 loop of HIV gp120 protein has an amino acid sequence that is SEQ ID NO.:3.
26 . The chimeric immunogen of claim 1 , wherein said chimeric immunogen further comprises at least a portion of an enzymatically inactive domain III of Pseudomonas aeruginosa exotoxin A and at least one of said antigens is inserted into said domain III.
27 . The chimeric immunogen of claim 26 , wherein said antigen inserted into domain III is a T cell antigen.
28 . The chimeric immunogen of claim 26 , wherein said Domain III of Pseudomonas aeruginosa exotoxin A comprises an endoplasmic reticulum retention signal.
29 . The chimeric immunogen of claim 26 , wherein said antigen that is inserted into said portion of an enzymatically inactive Domain III of Pseudomonas aeruginosa exotoxin A is nef protein of HIV.
30 . The chimeric immunogen of claim 29 , wherein said nef protein of HIV has an amino acid sequence that is SEQ ID NO.:4.
31 . The chimeric immunogen of claim 24 , wherein said chimeric immunogen further comprises at least a portion of an enzymatically inactive Domain III of Pseudomonas aeruginosa exotoxin A, at least one of said antigens is inserted into said Domain III, wherein said antigen that is inserted into said portion of Domain III of Pseudomonas aeruginosa exotoxin A is nef protein of HIV.
32 . The chimeric immunogen of claim 29 , wherein said V3 loop of HIV gp120 protein has an amino acid sequence that is SEQ ID NO.:3 and said nef protein of HIV has an amino acid sequence that is SEQ ID NO.:4.
33 . A polynucleotide encoding a chimeric immunogen according to claim 1 .
34 . An expression vector that comprises said polynucleotide of claim 33 operably linked to a promoter.
35 . The expression vector of claim 34 , wherein said promoter is a eukaryotic promoter.
36 . The expression vector of claim 34 , wherein said promoter is a prokaryotic promoter.
37 . The expression vector of claim 34 , wherein said promoter is an inducible promoter.
38 . The expression vector of claim 34 , wherein said expression vector further comprises a secretion signal that directs secretion of a polypeptide expressed from said expression vector from the cell in which said polypeptide is expressed.
39 . A transformed or transfected cell that comprises the expression vector of claim 34 .
40 . A composition comprising a chimeric immunogen according to claim 1 .
41 . The composition of claim 40 , wherein said composition further comprises a pharmaceutically acceptable diluent, excipient, vehicle, or carrier.
42 . The composition of claim 41 , wherein said composition is formulated for nasal or oral administration.
43 . A kit comprising the claim 41 , wherein said compositions is in a single-unit dosage form.
44 . The kit of claim 43 , further comprising instructions directing administration of said composition to a subject.
45 . A method for inducing an immune response in a subject, said method comprising contacting an apical epithelial membrane of said subject with an effective amount of a chimeric immunogen according to claim 1 .
46 . The method of claim 45 , wherein said immune response is a humoral immune response.
47 . The method of claim 45 , wherein said immune response is a secretory immune response.
48 . The method of claim 45 , wherein said immune response is a cell-mediated immune response.
49 . The method of claim 45 , wherein said chimeric immunogen is administered in the form of a pharmaceutical composition, wherein said pharmaceutical composition comprises said chimeric immunogen and a pharmaceutically acceptable diluent, excipient, vehicle, or carrier.
50 . The method of claim 49 , wherein said pharmaceutical composition is formulated for nasal or oral administration.
51 . The method of claim 50 , wherein said chimeric immunogen is administered to said subject nasally or orally.
52 . The method of claim 40 , wherein said subject is a mammal.
53 . The method of claim 52 , wherein said subject is a rodent, lagomorph or primate.
54 . The method of claim 53 , wherein said subject is a human.